TECH
Bio-Techne Corporation
NASDAQ · Healthcare · Biotechnology · US
$72.43
−0.03%Aug 22, 2026, 08:05 UTC
BlackRock Inc. disclosed a new stake of 14,025,816 shares in Bio-Techne Corp, valued at approximately $990,924,000, representing about 8.96% ownership, in a recent SEC filing.
Source:Aug 21, 2026, 02:03 UTC
As of August 20, 2026, the total margin trading balance on China's A-share market decreased by 1.248 billion yuan to 2.666356 trillion yuan, with net financing purchases led by Zhongji Innolight at 530 million yuan.
Source:Aug 12, 2026, 10:30 UTC
Bio-Techne Corporation reported its financial results for the fourth quarter of fiscal year 2026, with organic revenue increasing 3% to $321.2 million.
Jul 8, 2026, 10:30 UTC
Bio-Techne launched new additions to its R&D Systems AI-Engineered Designer Protein portfolio, including heat-stable and hyperactive proteins across fibroblast growth factor and interleukin cytokine families, to improve reproducibility and performance in cell therapy and cell culture workflows.
Source:Jun 26, 2026, 00:00 UTC
Bio-Techne Corp agreed to be acquired by Merck KGaA through a reverse triangular merger, with each share converted into $73.00 in cash.